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SObjective: End-stage lung disease and severe acute lung injury are complex entities that remain challenges to
manage. Therapies include early institution of mechanical ventilation with positive end-expiratory pressure,
permissive hypercapnia, pulmonary vasodilators, and complex fluid regimens. Veno-venous extracorporeal
membrane oxygenation is an available treatment option for these patients but, in its conventional form, can
be associated with significant complications. We present our early experience with an attempt to optimize
extracorporeal membrane oxygenation, emphasizing reduced adjunctive mechanical ventilatory support and
aggressive rehabilitation, with a goal of ambulation. This strategy has been enabled by the introduction of
a dual-lumen draw and return cannula placed via the internal jugular vein.
Methods: The first 10 patients (mean age of 45.3 years, 8 male) treated with this strategy between January 1,
2009, and October 1, 2009, were retrospectively reviewed. The ambulatory extracorporeal membrane oxygen-
ation strategy was initiated with an aim of minimal mechanical ventilation and aggressive rehabilitation. The
patients were intended to be weaned from all respiratory support or bridged to transplantation.
Results: The mean duration of extracorporeal membrane oxygenation was 20 (9–59) days, with average mean
blood flows of 3.5 (1.6–4.9) L/min, and levels of CO2 removal and O2 transfer of 228 (54–570) mL/min and 127
(36–529) mL/min, respectively. Six of 10 patients were weaned from respiratory support (N ¼ 4) or underwent
transplantation (N ¼ 2) and survived to discharge from the hospital. The remaining 4 patients died of sepsis
(N ¼ 3) and withdrawal of care after renal failure (N ¼ 1). Four of the 6 surviving patients were extubated
and ambulatory while still on extracorporeal membrane oxygenation. During that time, 3 of the 4 patients ex-
ercised at the bedside, with the remaining patient able to undergo full cardiopulmonary rehabilitation, including
treadmill walking.
Conclusions: Improvements in the durability of membrane blood oxygenators and pumps have prompted re-
newed consideration of extracorporeal membrane oxygenation in patients with severe lung disease. This report
describes an attempt to augment extracorporeal membrane oxygenation with the goal of ambulation byminimiz-
ing mechanical ventilatory support and using aggressive in-and-out-of-bed rehabilitation. (J Thorac Cardiovasc
Surg 2011;142:755-61)End-stage chronic lung disease and severe acute lung injury
are challenging to manage. Therapies include early institu-
tion of mechanical ventilation (MV) with positive end-
expiratory pressure, permissive hypercapnia, pulmonary
vasodilators, and complex fluid regimens.1,2
Veno-venous (VV) extracorporeal membrane oxygenation
(ECMO) has been used in nonresponsive patients with
some promising results3-6; however, there are significant
limitations associated with its current implementation.e Divisions of Cardiac Surgerya and Pulmonary Medicine,b University of
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The Journal of Thoracic and CaConventional ECMO requires cannulation of at least 1
femoral vessel, necessitating immobilization and physical
deconditioning. Patients receiving ECMO have seldom been
weaned from MV, increasing the risk of ventilator-
associated pneumonia and ventilator-induced lung injury,
even with minimal pressure/volume protocols.
With the recent development of a dual-lumen single
ECMO cannula, ECMO can be instituted via only right in-
ternal jugular (IJ) cannulation. Using this approach, we
have attempted to improve outcomes by minimizing me-
chanical ventilatory support and maximizing mobilization
and rehabilitation. We report our initial experience and les-
sons learned from the implementation of this strategy.MATERIALS AND METHODS
Patient Selection
The first 10 consecutive patients treated using an ambulatory ECMO
strategy were retrospectively reviewed with institutional review board ap-
proval (HP-00044921). Patient selection was done in collaboration with the
intensive care unit (ICU) and cardiac surgery teams. Enrollment criteriardiovascular Surgery c Volume 142, Number 4 755
TABLE 1. Patient characteristics
Patient no. Age (y) Gender BMI Diagnosis
1 31 Male 29.34 Pneumonia/ARDS
2 49 Male 22.14 COPD
3 67 Male 35.96 IPF
4 25 Female 24.41 Pneumonia/ARDS
5 62 Male 33.28 IPF
6 56 Male 34.89 IPF
7 39 Male 33.66 Pneumonia/ARDS
8 56 Male 26.14 pneumonia/ARDS
9 31 Male 28.86 IPF
10 35 Female 18.23 PAH/RVF
BMI, Body mass index; ARDS, acute respiratory distress syndrome; RVF, right
ventricular failure.
Abbreviations and Acronyms
COPD ¼ chronic obstructive pulmonary disease
ECMO ¼ extracorporeal membrane oxygenation
ICU ¼ intensive care unit
IJ ¼ internal jugular
IPF ¼ idiopathic pulmonary fibrosis
MV ¼ mechanical ventilation
PAH ¼ pulmonary arterial hypertension
VV ¼ veno-venous
General Thoracic Surgery Garcia et al
G
T
Swere severe respiratory failure despite maximal conventional therapy or
MV requirement with a disease process that has previously yielded greater
than 90% mortality once requiring MV (ie, idiopathic pulmonary fibrosis
[IPF]) (Table 1). Excluded were patients with a nonreversible disease pro-
cess, who were thought to be nontransplant candidates, or who had a body
surface area greater than 2.0 m2. Pre-ECMO physiologic, hemodynamic,
and ventilator variables are shown in Table 2.Cannulation for Extracorporeal Membrane
Oxygenation
Patients were transferred to the controlled environment of the operating
room and placed onto a fluoroscopic-enabled operating table. To allow for
mobilization while on ECMO, femoral cannulation was avoided. A dual-
lumen Avalon cannula (Avalon Laboratories, LLC, Rancho Dominguez,
Calif) was placed via the right IJ for both inflow from the superior and in-
ferior venae cavae and outflow to the mid-right atrium, as previously de-
scribed.7 Under general anesthesia, the IJ was localized with sonographic
guidance and a right IJ venopuncture was made with a 5F micro-
puncture needle (Cook Medical Inc, Bloomington, Ind). Over a guidewire,
a 5F Kumpe catheter (Cook Medical Inc) was then introduced and
positioned with the distal radiopaque tip extending 2 cm into the inferior
vena cava with transesophageal echocardiography and fluoroscopic guid-
ance and confirmation. In our first 2 patients, we created a 3- to 5-cm tunnel
anterior to the clavicle in the subcutaneous plane to an infraclavicular exit
site. Because of mild kinking of the cannula at the bend, a more gentle and
ergonomically improved supraclavicular exit site was used in subsequent
patients (N ¼ 8). The length of the tunnel was measured to allow the
‘‘Y’’ of the dual-lumen cannula to sit at the exit site for long-term position
stability. The soft guide wire was then exchanged for an Amplatz stiff wire
(Cook Medical Inc), and sequential dilation of the venous access was com-
pleted. The Avalon cannula (Avalon Laboratories, LLC) was positioned
over the wire with the ECMO inflow lumen fenestrations sitting in the
superior and inferior venae cavae, and the outflow to the mid-right atrium
toward the tricuspid valve (Figure 1). The cannula was connected to a crys-
talloid primed ECMO circuit, including a CentriMag pump (Levitronix,
Boston, Mass) and Quadrox oxygenator (Maquet Cardiovascular LLC,
San Jose, Calif). The system and oxygen tank were mounted to a wheeled
intravenous pole to facilitate patient mobility (Figure 2).
Mechanical Ventilation Management
Given the ability of the VV-configured ECMO to manage PCO2, primary
reference for weaning fromMVwas SAO2. FIO2 and positive end-expiratory
pressure were titrated to an oxygen saturation of 85% or greater. For con-
sideration of extubation, the patient needed to be awake and cooperative.
However, other standard evaluation variables, including PCO2, negative in-
spiratory force, tidal volumes, and rapid shallow breathing index were de-
emphasized to qualify for extubation. In patients in whom an extended
wean from MV was expected because of low SAO2, or if significant756 The Journal of Thoracic and Cardiovascular Surgpulmonary secretions were present making pulmonary toilet difficult, an
early, open tracheostomy was performed. If extubation was not immedi-
ately possible, full ECMO support was used with minimal MV support
(ARDSNet protocol was used).
Extracorporeal Membrane Oxygenation
Management
Anticoagulation and blood product transfusions. Heparin
was used for anticoagulation with a target activated clotting time of 160 to
180 seconds. If heparin-induced thrombocytopenia and thrombosis was
evident, argatroban was used with an activated partial thromboplastin
time goal of 2 to 2.5 times normal. To optimize oxygen-carrying capacity,
patients were transfused with packed red blood cells to maintain a hemato-
crit of at least 35% as a trigger, with a goal of 40%. Platelet transfusion was
reserved for a count of 20,000 or less or active bleeding to avoid sensitiza-
tion to human leukocyte antigen should the patient be or become
a candidate for transplant.
Extracorporeal Membrane Oxygenation Support
and Weaning
Pump speed was titrated to maintain the highest flow return to ensure
SAO2 with a maximum measured inflow negative pressure of 85 mm Hg
or less. For patients with reversible lung disease, intended as a bridge to
recovery, ECMO was weaned when clinically appropriate as determined
by both the ICU and cardiac surgery teams. The ECMO FIO2 was gradually
turned down to 0.21 for 2 hours. When successful, the sweep was then
turned off for an additional 2 hours, allowing complete recirculation. If
adequate oxygenation and ventilation were maintained, ECMO decannula-
tion was performed. The patient was placed in the Trendelenburg position
to decrease risk air embolism, a single 0 silk U stitch was placed, and the
cannula was pulled at the bedside. For patients qualifying for lung trans-
plantation with nonreversible disease processes, full ECMO support was
continued until transplantation.
Data Collection
Data were collected from electronic medical records, critical care flow-
sheets, ventilator flowsheets, and perfusion flowsheets. Pre-ECMO MV
settings are the last ventilator settings recorded on the critical care flow-
sheet before the ECMO circuit was initiated.RESULTS
Extracorporeal Membrane Oxygenation Variables
A smaller dual-lumen cannula (23F) was used for pa-
tients (N ¼ 2) with primarily hypercapnea, who requiredery c October 2011
TABLE 2. Pre-extracorporeal membrane oxygenation patient variables
Patient no.
ABG Mechanical ventilation Adjunct therapies Hemodynamic stability
PAO2 PCO2 pH Duration FIO2 PEEP Nitric oxide Steroids Paralysis Pressors
SBP
<90 mm Hg
RV
dysfunction
1 32 89 7.30 6 1.0 * Y Y Y Y Y N
2 89 75 7.39 15 0.6 5 Y Y Y Y N N
3 93 79 7.35 6 0.7 10 Y Y N Y Y Y
4 82 45 7.31 16 1.0 y Y Y Y Y Y N
5 154 59 7.39 4 0.7 8 Y Y N Y Y Y
6 51 60 7.43 3 1.0 * Y N Y Y Y Y
7 41 86 7.23 38 1.0 15 Y N N Y Y N
8 108 63 7.28 5 0.6 12 Y Y N Y Y N
9 54 67 7.33 6 0.8 5 Y Y Y Y Y Y
10 49 23 7.45 1 1.0 * Y Y N Y Y Y
PEEP, Positive end-expiratory pressure; SBP, systolic blood pressure; RV, right ventricular. *Patient on airway pressure release ventilation. yPatient on high-frequency oscillator.
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for patients with severe hypoxia, who required higher flows.
Initially, we attempted to use a 29F cannula, but were lim-
ited to a mean flow of 3.3 (3.2–3.5) L/min, and thus a mean
O2 transport of 115 (53–193) mL/min. Subsequently, the
31F cannulae became our size of choice for patients with
high oxygen transfer requirements. The rates of blood
flow averaged 3.5 (1.6–4.9) L/min in this series. Rates ofFIGURE 1. Insertion of the dual-lumen cannula into the IJ vein via tunneling fro
the subtle curve of the tunneled cannula. Inflow to the ECMO circuit is from the
mid-cannula at the superior vena cava–right atrial junction. Outflow between th
The Journal of Thoracic and CaO2 transfer and CO2 removal were 127 (36–529) mL/min
and 228 (54–570) mL/min, respectively. The duration of
ECMO was 20  15 days.
Outcomes
Six of the 10 patients were successfully weaned fromMV
while still on ECMO (Table 4). Four of the 6 patients
required tracheostomy for a slower wean and assistancem the right subclavicular chest (supraclavicular tunneling not shown). Note
tip of the cannula located in the inferior vena cava and fenestrations in the
ese 2 points is directed at the tricuspid valve.
rdiovascular Surgery c Volume 142, Number 4 757
FIGURE 2. Ambulatory ECMO circuit.
TABLE 3. Extracorporeal membrane oxygenation variables
Cannula size
23F 2
29F 1
31F 7
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Swith clearance of airway secretions. Of the 6 patients who
were weaned from MV support, 3 were assisted to a chair
for in-room rehabilitation, and 1 patient, who was treated
primarily for unresponsive CO2 retention, underwent exten-
sive rehabilitation, including treadmill walking. One patient
with IPF and 1 patient with chronic obstructive pulmonary
disease (COPD) were bridged to transplant, whereas 3 pa-
tients with acute respiratory distress syndrome and 1 patient
with pulmonary arterial hypertension (PAH) were success-
fully bridged to recovery.ECMO duration (d) 20  15
Flow (L/min) 3.5 (1.6–4.9)
CO2 removal (mL/min) 228 (54–570)
O2 transfer (mL/min) 127 (36–529)
Variables are represented as N, mean  standard deviation, or mean and (range).Major Complications
A major bleeding event was observed in 4 of the patients
with a mean packed red blood cell use of 48.75 (19–118)758 The Journal of Thoracic and Cardiovascular Surgunits (Table 5). In 1 early patient, the bleeding event was
secondary to a right atrial perforation that occurred during
cannula positioning with echocardiographic guidance
alone, and required operative repair. Two patients requiredery c October 2011
TABLE 4. Outcomes
Patient
no.
MV support on
ECMO duration (d) Tracheostomy
Out-of-bed
rehabilitation
ICU
LOS
Hospital
LOS
30-d
mortality Transplanted
1-y
mortality
1-y
outcome
1 12 N – 12 12 Y – Y Death
2 12 Y Y 25 47 – Y – Home
3 9 N – 9 9 Y – Y Death
4 36 Y – 69 72 – – – Home
5 2 N Y 25 25 – Y Y Death*
6 25 N – 25 25 Y – Y Death
7 20 Y – 40 42 _ – – Home
8 9 Y Y 40 40 – – Y Death
9 30 N – 30 30 Y – Y Death
10 9 N Y 37 37 – – – Home
ICU and hospital LOS include only post-ECMO. LOS, Length of stay. *Sepsis, after bilateral lung transplantation.
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bleeding, and 1 patient had a significant gastrointestinal
bleed. All patients who received a tracheostomy (N ¼ 2)
while receiving ECMO support and, therefore, anticoagula-
tion therapy, had some surgical site bleeding. This was not
observed in patients who ‘‘prophylactically’’ received
a tracheostomy before ECMO support (N ¼ 2).
Two patients had a stroke. Both patients had known atrial
septal defects, and presumably experienced a paradoxical
embolic stroke. Full recovery was seen in one of them.
Thirty-day mortalities were secondary to sepsis with multi-
organ system failure (N¼ 3) and after withdrawal of care by
family once significant renal failure developed in a patient
(N ¼ 1).DISCUSSION
The present study attempted to improve the standard VV
ECMO support for patients with severe pulmonary failure
by using a single cannula system to allow minimal MV sup-
port and aggressive rehabilitation. In this initial experience,
6 of the 10 patients were successfully weaned from MV
while supported with ECMO and bridged to recovery or
transplantation. Of those 6 patients, 4 were able to meaning-
fully participate in active rehabilitation.TABLE 5. Major complications
Major bleeding event 4
Right atrial perforation 1
Epistaxis/endobronchial bleed 2
GI bleed 1
Cannula-related infection 0
HITT 1
CVA 2
30-d mortality 4
Sepsis with MSOF 3
Family withdrawal of care 1
Variables are represented as N. GI,Gastrointestinal;HITT, heparin-induced thrombo-
cytopenia and thrombosis; CVA, cerebrovascular accident;MSOF,multisystem organ
failure.
The Journal of Thoracic and CaThe rationale for our ambulatory ECMO strategy empha-
sizing ambulation was to minimize deconditioning and
ventilator-associated morbidity. There is sufficient evidence
that patients confined to bed in an ICU setting undergo sig-
nificant neuromuscular degeneration,8 and weakness of the
large proximal and respiratory muscle leads to prolonged
ventilation.9 Several studies have suggested that early am-
bulation is advantageous for patients in the ICU. In one pro-
spective cohort study, an early mobilization protocol
resulted in fewer days in bed, shorter ICU length of stay
(5.5 vs 6.9 days), and decreased overall hospital length of
stay (11.2 vs 14.5 days).10 In a recent randomized con-
trolled trial, early activity led to fewer days of delirium
and less time on a ventilator.11 Taken together, these studies
imply that early activity may lead to improved outcomes in
patients in the ICU. This is particularly important for lung
transplantation candidates, in whom there is a direct corre-
lation between functional status and exercise capacity with
outcomes.12 Although rehabilitation while on MV has been
reported,13 its use in patients requiring significant MV
support while at rest is not a realistic goal. Also, rehabilita-
tion while on MV has not been shown to reduce the risk of
ventilator-induced lung injury, for which there is ample lit-
erature on its detriment to pulmonary recovery.14-17 In our
cohort, the mean length of intubation and MV before
ECMO support was 10 days. Many of these patients may
have already had significant physical deconditioning and
ventilator-induced lung injury. Perhaps earlier implementa-
tion of ECMO in these patients may be necessary to im-
prove outcomes, and large randomized trials are critically
needed in this area.
Several important lessons were learned from our early
experience. As expected, patient selection seems to be
one of the most central drivers of outcome. This was a di-
verse patient cohort with multiple causes of pulmonary
failure. Patients with pneumonia/acute respiratory distress
syndrome fared best, with 3 of 4 surviving to 1 year. Out-
comes were poor in patients with IPF. Three of 4 patients
died while awaiting transplantation, with a mean ECMOrdiovascular Surgery c Volume 142, Number 4 759
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of sepsis 2 months after bilateral lung transplantation.
Significant right ventricular failure developed in the pa-
tients with IPF, and, despite adequate ECMO flows, they
had progressive and rapid hypotension and hypoxia. This
concurs with previous reports of dismal outcomes for
patients with IPF once they require MV.18-20 In contrast,
2 patients of interest in this cohort, previously described,
were one with COPD21 and one with PAH.22 The patient
with COPD was an extreme example of that disease pro-
cess. He was unable to maintain a PCO2 of less than 100
mmHg unless fully sedated, despite tracheostomy andmax-
imal MV. After ECMO initiation, his PCO2 was corrected,
and the patient was able to participate in full cardiopulmo-
nary rehabilitation before successful transplantation. At the
time of referral for ECMO, the patient with PAH was
severely hypoxic and acute right ventricular failure had
developed, associated with an akinetic and ‘‘smoke-filled’’
echocardiogram. Normally, veno-arterial ECMO would be
the ECMO strategy of choice for this case. However, the
patient had a large atrial septal defect and preferential
shunting of right atrial blood to the left atrium. By placing
the dual-lumen cannula with the outflow orifice juxtaposed
to the atrial septal defect, we successfully delivered fully
oxygenated blood to the left atrium. This permitted
adequate left-sided preload and provided shock-reversing
oxygenation. Soon the distressed right ventricle improved
and progressively could power venous return through the
lungs. The patient recovered with the addition of pharmaco-
logic therapies for PAH. The success of this patient may be
an important stepping stone for other patient populations
with right ventricular failure, such as our morbid patients
with IPF.
There were 2 major changes in the technique of ECMO
cannula insertion. The first was the consistent use of both
transesophageal echocardiography and fluoroscopy during
insertion. This was changed after advancement of the
cannula ‘‘blindly’’ led to a right atrial perforation requiring
operative intervention. There was no incidence of post-
insertion cannula perforation or malpositioning with patient
movement, as has been anecdotally described at other cen-
ters. We ascribe this to the tunneling of the cannula to hub
the ‘‘Y’’ portion, diminishing advancement or withdrawal.
The second technique change was in the tunneling itself.
Although a subclavicular lay of the cannula would be
ergonomic for patient mobility, after the first insertion, an
intermittent, positional kinking of the cannula was noted.
Subsequently, supraclavicular tunneling of the catheter
was used, which avoided kinking but still offered an ergo-
nomic lay. All subsequent patients had similar insertions
with only varying cannula size based on presumed need
of ventilation versus oxygenation.
A tracheostomywas required in 4 of the 6 patients weaned
from mechanical ventilatory support. Tracheostomy both760 The Journal of Thoracic and Cardiovascular Surgincreased patient comfort during the MV weaning process
and allowed for better pulmonary toilet. It is still unclear,
however, which patients will ultimately require a tracheos-
tomy with ECMO support. Nevertheless, on the basis of
this small experience, patients with already prolonged ven-
tilation or particularly severe disease may benefit from the
tracheostomy being performed before the initiation of
ECMO and anticoagulation.
Obtaining a balance between circuit and systemic throm-
bosis and hemorrhage in ECMO-supported patients is one
of the most difficult and frustrating management issues.
We observed almost universal endobronchial bleeding,
which was major in 2 patients. In addition to careful titra-
tion of anticoagulation, diligent monitoring of fibrinogen
levels and platelet function (thromboelastography and
platelet function assay) has become mandatory to avoid
these significant episodes. Additional simple consider-
ations, including the use of low suction and red rubber cath-
eters for naso-oropharyngeal and endotracheal clearance,
have also reduced their incidence.
Limitations
The current series has limitations. It is small, retrospec-
tive, and descriptive; and the end point of extubation and
ambulation was not met by all the patients. We believe
few will argue the rationale for developing a strategy of
progressive rehabilitation in the previously bed- and
ventilator-bound ECMO-supported patient. The lessons
we have learned are important not only for our own program
but for those pursuing ECMO for adult respiratory support.
CONCLUSIONS
Further advancements in ECMO are required. The aug-
mentation of ECMO with rehabilitation and minimal
mechanical ventilatory support is feasible and may be ben-
eficial in some patients. These early results, although prom-
ising, are only hypothesis generating and will require larger
prospective trials before this strategy should receive wide-
spread adoption.
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Dr Mark Danton (Glasgow, Scotland). We have had experi-
ence with this cannula in neonates and have been concerned about
the incidence of perforation. One case occurred at implantation, as
you have had, but another case occurred late down the line when
the patient was having physiotherapy on the lungs. The cannula
was well placed at the time of implantation with the distal end
in the inferior vena cava but had subsequently migrated, and
with the physiotherapy and the up and downmovement had caused
a right atrial perforation and required repair. So my question to you
is that once you have positioned these catheters, cannulas, do youThe Journal of Thoracic and Casubsequently monitor their position and review their position,
particularly when you are starting to mobilize the patient?
Dr Kon. In our experience, we only had a single perforation. It
was during cannula placement, and that, again, was before fluoros-
copy and transesophageal echocardiography were used in every
case for placement. In regard to movement of the cannula during
physiotherapy, we routinely tunnel our catheter so it is actually
hubbed at the end of the tunnel and secured at that point with
multiple sutures. We then monitor its placement with daily chest
x-rays, which seemed to haveworked, and we haven’t had any can-
nula dislodgement or movement.
Dr Thoralf Sundt (Rochester, Minn). Patients with pulmonary
hypertension are a problem for a lot of us, and that is where we see
the need for ECMO frequently in bridging to transplant. I am a little
confused. Can you help me understand how aVV system helps you
deal with pulmonary hypertension? Usually their mode of exit is
right heart failure.
Dr Kon. That patient actually had a wide open atrial septal
defect, and I guess you could consider it pseudo-venoarterial
ECMO in that patient, because with that central orifice in the right
atrium, it essentially just flows right across into the left atrium,
thereby bypassing the lungs.
Dr Bryan Meyers (St Louis, Mo). This is a type of therapy that
is currently in use for other indications, and what you are propos-
ing in addition to the new technology or the specific technology is
extending the indications, and it is based on an assessment of the
patient’s poor prognosis. I think in other areas we have objective
risk scores. You have 2 intensivists who assure you that the prog-
nosis is poor, but in assessing the value of something like this, it
would be nice to have some objective estimate of that patient’s
prognosis to know what difference you have made when all is
said and done.
Dr Kon. Thank you for the comment. I agree completely.
Dr Bansi Koul (Lund, Sweden). Thanks for a wonderful pre-
sentation and excellent results. My short question to you is about
what I observed from your data that you have increasingly been
using 31F cannulas, especially in the later part of your
experience. Was it because the blood flows were not sufficient
to oxygenate the patient or can you give us some information
idea about the extracorporeal recirculation of the oxygenated
blood within this setup?
DrKon.We did use 31F routinely toward the end of this cohort,
and it was in fact because it is hard to get flows up to 4 liters with
these smaller cannulas, and we had minimal to no recirculation in
this circuit, because the fenestrations sit in the inferior and superior
venae cavae and then the outflow is directly toward the tricuspid
valve.rdiovascular Surgery c Volume 142, Number 4 761
